文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌中度大分割根治性放疗的人群层面使用趋势

Population-Level Uptake of Moderately Hypofractionated Definitive Radiation Therapy in the Treatment of Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-05-08

该研究基于澳大利亚新南威尔士州2014至2018年门诊放疗数据,纳入4915例接受根治性外照射且未照射淋巴结的前列腺癌患者,分析中度大分割放疗(HypoRT)使用变化的影响因素。结果显示HypoRT使用率从2014年5.2%升至2018年40.3%,但放疗医生、治疗机构和距离是影响使用的主要因素,机构间和医生间差异仍显著。

要点

  • HypoRT使用率从2014年5.2%增至2018年40.3%,但仍存在机构与医生间差异。
  • 放疗医生、治疗机构和治疗距离是影响HypoRT使用的主要因素。
  • 该研究未按前列腺癌风险分层,为主要局限性。

核心结论

  • 2014至2018年间HypoRT使用率显著增加,但在治疗机构和放疗医生之间仍存在差异。

研究设计与样本

  • 基于澳大利亚新南威尔士州2014至2018年公立和私立机构门诊放疗数据的回顾性连续队列研究,纳入4915例接受根治性外照射且未照射淋巴结的任何风险前列腺癌患者。
  • 采用三级分层逻辑回归模型分析影响HypoRT使用的因素,效应以校正、中位或区间比值比报告。

主要发现

  • 4915例患者中4053例(82.5%)接受常规分割,862例(17.5%)接受HypoRT。
  • HypoRT使用率从2014年的5.2%上升至2018年的40.3%。
  • 放疗医生、治疗机构以及治疗中心距离增加对HypoRT使用影响最大。

临床怎么用

  • 前列腺癌根治性外照射中HypoRT使用率呈上升趋势,但需关注机构和医生间的使用差异。
  • 治疗距离和机构因素影响HypoRT选择,提示需制定策略减少临床医生间差异。

局限性

  • 研究缺乏按前列腺癌风险分层的分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recent evidence shows the noninferiority of hypofractionated radiation therapy regimens compared with conventional regimens in the treatment of prostate cancer (PCa). Hypofractionation has benefits for both the patient and health care system, because of the shorter treatment duration. Despite this advantage, the uptake of hypofractionation can be slow. Here we investigate the factors influencing the changing use of moderate hypofractionation (HypoRT) for the treatment of PCa. METHODS AND MATERIALS: We conducted a population-based, retrospective, consecutive cohort study using the 2014 to 2018 Outpatient Radiation Oncology Data from public and private treatment facilities in New South Wales, Australia. Included participants had a PCa diagnosis of any risk, and they completed curative-intent external beam radiation therapy without treatment to lymph nodes. Factors potentially affecting use of HypoRT were examined using a 3-level hierarchical logistic regression model. The effects were reported using adjusted, median, or interval odds ratios. RESULTS: The study included 4915 patients. Of these, 4053 patients (82.5%) received conventional fractionation, and 862 patients (17.5%) received HypoRT. HypoRT utilization increased from 5.2% in 2014 to 40.3% in 2018. The treating radiation oncologist, treatment facility, and increasing distance to treatment centers had the greatest influence on HypoRT uptake. The main limitation was the lack of stratification by PCa risk categorization. CONCLUSIONS: Although HypoRT uptake has considerably increased between 2014 and 2018, it remains variable among facilities and treating radiation oncologists. Strategies are being explored to reduce inter-clinician variability.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Nithiyananthan K, Creighton N, Currow D, et al. Population-Level Uptake of Moderately Hypofractionated Definitive Radiation Therapy in the Treatment of Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021. PMID: 33974884. doi:10.1016/j.ijrobp.2021.04.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。